Brain Cancer

ON-TRK: PrOspective Non-Interventional Study in Patients with Locally Advanced or Metastatic TRK Fusion Cancer Treated with Larotrectinib

Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (NIVO-MR2) Induction followed by Lenalidomide and Nivolumab Maintenance in Primary CNS Lymphoma

Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas

A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatically Hypermutated Recurrent Glioblastoma

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients

A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)

Neuroblastoma Biology Studies

Molecular Analysis for Combination Therapy Choice (ComboMATCH)

A Pivotal Randomized, Open-Label Study of Optune (TTFields, 200KHZ) Concomitant with Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma

A Multicenter Randomized Phase III Trial on Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme (INTRAGO II)

Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study

A Phase I/II study of Radiation/Temozolomide and Immunotherapy with Daratumumab to Improve Antitumor Efficacy in Glioblastoma (PRIDE)